source,date,assertionType,evidenceType,exactText,modality,statementType,drug1Lab,drug1Type,drug1Role,dose1,drug2Lab,drug2Type,drug2Role,dose2,objectRegimens,objectFormulation,objectDuration,preciptRegimens,preciptFormulation,preciptDuration,numOfParticipants,auc,aucType,aucDirection,cl,clType,clDirection,cmax,cmaxType,cmaxDirection,t12,t12Type,t12Direction
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html,2015-09-16 15:31:12 -0400,DDI-clinical-trial,evidence-supports,"Digoxin–In a placebo-controlled trial in normal volunteers, administration of sertraline for 17 days (including 200 mg/day for the last 10 days) did not change serum digoxin levels or digoxin renal clearance.",ncit:negative,ncit:quantitative,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,200,UNK,UNK,Unk,Daily,Oral,17,10,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html,2015-09-16 15:31:12 -0400,drug-drug-interaction,evidence-supports,"In a placebo-controlled trial in normal volunteers, the administration of two doses of sertraline did not significantly alter steady-state lithium levels or the renal clearance of lithium.",ncit:negative,ncit:Qualitative,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,lithium,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html,2015-09-16 15:31:12 -0400,DDI-clinical-trial,evidence-supports,"Cimetidine–In a study assessing disposition of sertraline (100 mg) on the second of 8 days of cimetidine administration (800 mg daily), there were significant increases in sertraline mean AUC (50%), Cmax (24%) and half-life (26%) compared to the placebo group. The clinical significance of these changes is unknown.",ncit:positive,ncit:quantitative,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,100,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,800,SD,Oral,2,Daily,Oral,8,Unk,50,Percent,Increase,Unk,UNK,UNK,24,Percent,Increase,26,Percent,Increase
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html,2015-09-16 15:31:12 -0400,DDI-clinical-trial,evidence-supports,"Hypoglycemic Drugs–In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose. Sertraline administration did not noticeably change either the plasma protein binding or the apparent volume of distribution of tolbutamide, suggesting that the decreased clearance was due to a change in the metabolism of the drug. The clinical significance of this decrease in tolbutamide clearance is unknown.",ncit:positive,ncit:quantitative,tolbutamide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,200,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,1000,SD,IV,1,Daily,Oral,22,Unk,Unk,UNK,UNK,16,Percent,Decrease,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html,2015-09-16 15:31:12 -0400,DDI-clinical-trial,evidence-supports,"Drugs Metabolized by P450 3A4–In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).",ncit:positive,ncit:quantitative,cisapride,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,200,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,UNK,UNK,Unk,QD,Oral,Unk,Unk,35,Percent,Decrease,Unk,UNK,UNK,35,Percent,Decrease,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html,2015-09-16 15:31:12 -0400,DDI-clinical-trial,evidence-supports,"In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p < 0.03). There was a 23% increase in Tmax for desmethyldiazepam in the sertraline group compared to a 20% decrease in the placebo group (p < 0.03). The clinical significance of these changes is unknown.",ncit:positive,ncit:quantitative,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,50-200,diazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Unk,UNK,IV,Unk,Daily,Oral,21,Unk,Unk,UNK,UNK,32,Percent,Decrease,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html,2015-09-16 15:31:12 -0400,DDI-clinical-trial,evidence-supports,"n a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.) co-administration to steady state was associated with a mean increase in pimozide AUC and Cmax of about 40%, but was not associated with any changes in EKG. Since the highest recommended pimozide dose (10 mg) has not been evaluated in combination with sertraline, the effect on QT interval and PK parameters at doses higher than 2 mg at this time are not known. While the mechanism of this interaction is unknown, due to the narrow therapeutic index of pimozide and due to the interaction noted at a low dose of pimozide, concomitant administration of sertraline and pimozide should be contraindicated (see ",ncit:positive,ncit:quantitative,pimozide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,200,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,2,SD,Oral,1,QD,Oral,Unk,Unk,40,Percent,Increase,Unk,UNK,UNK,40,Percent,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html,2015-09-16 15:31:12 -0400,drug-drug-interaction,evidence-supports,"Drugs Metabolized by P450 3A4–In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).",ncit:negative,ncit:Qualitative,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html,2015-09-16 15:31:12 -0400,drug-drug-interaction,evidence-supports,"Drugs Metabolized by P450 3A4–In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).",ncit:negative,ncit:Qualitative,terfenadine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 11:32:07 -0400,drug-drug-interaction,evidence-supports,Coadministration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy),ncit:positive,ncit:Qualitative,fosamprenavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 11:32:07 -0400,drug-drug-interaction,evidence-supports,Coadministration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy).,ncit:positive,ncit:Qualitative,ritonavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 11:31:14 -0400,DDI-clinical-trial,evidence-supports,"Daily oral dosing of paroxetine (30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state. If anticholinergic effects are seen, the dose of procyclidine should be reduced.",ncit:positive,ncit:quantitative,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,5,procyclidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,30,Daily,Oral,Unk,Daily,Oral,Unk,Unk,35,Percent,Increase,Unk,UNK,UNK,37,Percent,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 11:31:14 -0400,DDI-clinical-trial,evidence-supports,"In a study where propranolol (80 mg twice daily) was dosed orally for 18 days, the established steady-state plasma concentrations of propranolol were unaltered during coadministration with paroxetine (30 mg once daily) for the final 10 days. The effects of propranolol on paroxetine have not been evaluated (see ADVERSE REACTIONS: Postmarketing Reports).",ncit:negative,ncit:quantitative,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,30,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,80,BID,Oral,18,Daily,Oral,10,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 11:31:14 -0400,drug-drug-interaction,evidence-supports,"Under steady-state conditions, diazepam does not appear to affect paroxetine kinetics. The effects of paroxetine on diazepam were not evaluated.",ncit:negative,ncit:Qualitative,diazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 11:21:10 -0400,DDI-clinical-trial,evidence-supports,"When a single oral 30 mg dose of paroxetine was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to paroxetine administered alone. In a separate study, when a single oral 300 mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone. Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustments are considered necessary when these drugs are coadministered; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS: Postmarketing Reports).",ncit:positive,ncit:quantitative,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,30,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,300,SD,Oral,1,Daily,Oral,14,Unk,12,Percent,Decrease,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 11:21:10 -0400,DDI-clinical-trial,evidence-supports,"Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.",ncit:positive,ncit:quantitative,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,20,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,4-8,Daily,Oral,Unk,Daily,Oral,Unk,Unk,10,Percent,Decrease,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 11:21:10 -0400,drug-drug-interaction,evidence-supports,"An in vivo interaction study involving the coadministration under steady-state conditions of paroxetine and terfenadine, a substrate for cytochrome CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics.",ncit:negative,ncit:Qualitative,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,terfenadine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 11:21:10 -0400,drug-drug-interaction,evidence-supports,"A multiple-dose study has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate. However, due to the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with lithium.",ncit:negative,ncit:Qualitative,lithium carbonate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 11:21:10 -0400,DDI-clinical-trial,evidence-supports,"The steady-state pharmacokinetics of paroxetine was not altered when administered with digoxin at steady state. Mean digoxin AUC at steady state decreased by 15% in the presence of paroxetine. Since there is little clinical experience, the concurrent administration of paroxetine and digoxin should be undertaken with caution.",ncit:positive,ncit:quantitative,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Unk,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,UNK,UNK,Unk,UNK,UNK,Unk,Unk,15,Percent,Decrease,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 11:21:10 -0400,DDI-clinical-trial,evidence-supports,"The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state. In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours. This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone. Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when it is given with paroxetine.",ncit:positive,ncit:quantitative,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,20,atomoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,20,Q12,Oral,Unk,Daily,Oral,Unk,Unk,6-8,Fold,Increase,Unk,UNK,UNK,3-4,Fold,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 11:21:10 -0400,DDI-clinical-trial,evidence-supports,"Many drugs, including most drugs effective in the treatment of major depressive disorder (paroxetine, other SSRIs and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6. Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme. In most patients (>90%), this CYP2D6 isozyme is saturated early during dosing with paroxetine. In 1 study, daily dosing of paroxetine (20 mg once daily) under steady-state conditions increased single dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively. ",ncit:positive,ncit:quantitative,desipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,20,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,100,SD,Oral,Unk,Daily,Oral,Unk,Unk,5,Fold,Increase,Unk,UNK,UNK,2,Fold,Increase,3,Fold,Increase
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 11:21:10 -0400,DDI-clinical-trial,evidence-supports,"Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.",ncit:positive,ncit:quantitative,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,4-8,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,20,Daily,Oral,Unk,Daily,Oral,Unk,Unk,4,Fold,Increase,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 11:03:10 -0400,DDI-clinical-trial,evidence-supports,"Phenobarbital induces many cytochrome P450 (oxidative) enzymes. When a single oral 30 mg dose of paroxetine was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone. The effect of paroxetine on phenobarbital pharmacokinetics was not studied. Since paroxetine exhibits nonlinear pharmacokinetics, the results of this study may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustment of paroxetine is considered necessary when coadministered with phenobarbital; any subsequent adjustment should be guided by clinical effect.",ncit:positive,ncit:quantitative,phenobarbital,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,30,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,100,SD,Oral,1,Daily,Oral,14,Unk,25,Percent,Decrease,Unk,UNK,UNK,Unk,UNK,UNK,38,Percent,Decrease
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 11:03:10 -0400,DDI-clinical-trial,evidence-supports,"When a single oral 30 mg dose of paroxetine was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to paroxetine administered alone. In a separate study, when a single oral 300 mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone. Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustments are considered necessary when these drugs are coadministered; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS: Postmarketing Reports).",ncit:positive,ncit:quantitative,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,30,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,300,SD,Oral,1,Daily,Oral,14,Unk,50,Percent,Decrease,Unk,UNK,UNK,Unk,UNK,UNK,35,Percent,Decrease
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 11:00:37 -0400,DDI-clinical-trial,evidence-supports,"Cimetidine inhibits many cytochrome P450 (oxidative) enzymes. In a study where paroxetine (30 mg once daily) was dosed orally for 4 weeks, steady-state plasma concentrations of paroxetine were increased by approximately 50% during coadministration with oral cimetidine (300 mg three times daily) for the final week. Therefore, when these drugs are administered concurrently, dosage adjustment of paroxetine after the 20 mg starting dose should be guided by clinical effect. The effect of paroxetine on cimetidine’s pharmacokinetics was not studied.",ncit:positive,ncit:quantitative,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,30,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,300,Daily,Oral,28,TID,Oral,7,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 10:51:15 -0400,DDI-clinical-trial,evidence-supports,"In a controlled study of healthy volunteers, after paroxetine was titrated to 60 mg daily, coadministration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmax of 62%, compared to pimozide administered alone. The increase in pimozide AUC and Cmax is due to the CYP2D6 inhibitory properties of paroxetine. Due to the narrow therapeutic index of pimozide and its known ability to prolong the QT interval, concomitant use of pimozide and paroxetine is contraindicated (see CONTRAINDICATIONS).",ncit:positive,ncit:quantitative,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,2,pimozide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,60,SD,Oral,1,Daily,Oral,Unk,Unk,151,Percent,Increase,Unk,UNK,UNK,62,Percent,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 10:25:07 -0400,drug-drug-interaction,evidence-supports,"In vitro drug interaction studies reveal that paroxetine inhibits CYP2D6. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 including desipramine, risperidone, and atomoxetine (see PRECAUTIONS: Drug Interactions).",ncit:positive,ncit:Qualitative,desipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 10:25:07 -0400,drug-drug-interaction,evidence-supports,"In vitro drug interaction studies reveal that paroxetine inhibits CYP2D6. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 including desipramine, risperidone, and atomoxetine (see PRECAUTIONS: Drug Interactions).",ncit:positive,ncit:Qualitative,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html,2015-09-14 10:25:07 -0400,drug-drug-interaction,evidence-supports,"In vitro drug interaction studies reveal that paroxetine inhibits CYP2D6. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 including desipramine, risperidone, and atomoxetine (see PRECAUTIONS: Drug Interactions)",ncit:positive,ncit:Qualitative,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,atomoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html,2015-09-10 15:01:13 -0400,DDI-clinical-trial,evidence-supports,"In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with 5- and 8-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone. Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine. ",ncit:positive,ncit:quantitative,fluvoxamine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,40,tacrine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,100,SD,Oral,1,Daily,Oral,Unk,13,8,Fold,Increase,Unk,UNK,UNK,5,Fold,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html,2015-09-10 15:01:13 -0400,DDI-clinical-trial,evidence-supports,"Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol. Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion. ",ncit:negative,ncit:quantitative,atenolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,100,fluvoxamine maleate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,100,Daily,Oral,Unk,Daily,Oral,Unk,6,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html,2015-09-10 15:01:13 -0400,drug-drug-interaction,evidence-supports,"Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine. Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced. ",ncit:positive,ncit:Qualitative,clomipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,fluvoxamine maleate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html,2015-09-10 15:01:13 -0400,DDI-clinical-trial,evidence-supports,"A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction. On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone. ",ncit:negative,ncit:quantitative,fluvoxamine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,4,lorazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,50,BID,Oral,Unk,SD,Oral,1,12,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html,2015-09-10 15:01:13 -0400,DDI-clinical-trial,evidence-supports,"Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean 5-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure. ",ncit:positive,ncit:quantitative,fluvoxamine maleate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,160,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,100,Daily,Oral,Unk,Daily,Oral,Unk,Unk,Unk,UNK,UNK,Unk,UNK,UNK,5,Fold,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html,2015-09-10 15:01:13 -0400,DDI-clinical-trial,evidence-supports,Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin. ,ncit:positive,ncit:quantitative,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,100,fluvoxamine maleate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,1.25,SD,IV,1,Daily,Oral,18,8,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html,2015-09-10 15:01:13 -0400,DDI-clinical-trial,evidence-supports,"A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction. On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone. ",ncit:negative,ncit:quantitative,lorazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,4,fluvoxamine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,50,SD,Oral,1,BID,Oral,Unk,12,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html,2015-09-10 15:01:13 -0400,drug-drug-interaction,evidence-supports,"Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine. Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced. ",ncit:positive,ncit:Qualitative,amitriptyline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,fluvoxamine maleate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html,2015-09-10 15:01:13 -0400,drug-drug-interaction,evidence-supports,"Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine. Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.",ncit:positive,ncit:Qualitative,imipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,fluvoxamine maleate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html,2015-09-10 14:41:16 -0400,DDI-clinical-trial,evidence-supports,"Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. The magnitude of the impact of this factor is small in comparison to the overall variability between individuals, and therefore dose modification is not routinely recommended. ",ncit:positive,ncit:quantitative,Fluoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,olanzapine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,60,UNK,UNK,Unk,Daily,Oral,8,Unk,Unk,UNK,UNK,16,Percent,Decrease,16,Percent,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html,2015-09-10 14:41:16 -0400,DDI-clinical-trial,evidence-supports,"Drugs Metabolized by CYP3A4 — In an in vivo interaction study involving coadministration of fluoxetine with single doses of terfenadine (a CYP3A4 substrate), no increase in plasma terfenadine concentrations occurred with concomitant fluoxetine. ",ncit:negative,ncit:quantitative,fluoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,terfenadine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Unk,SD,UNK,1,UNK,UNK,Unk,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html,2015-09-10 14:36:47 -0400,drug-drug-interaction,evidence-supports,Benzodiazepines — The half-life of concurrently administered diazepam may be prolonged in some patients [see Clinical Pharmacology (12.3)]. Coadministration of alprazolam and fluoxetine has resulted in increased alprazolam plasma concentrations and in further psychomotor performance decrement due to increased alprazolam levels. ,ncit:positive,ncit:Qualitative,fluoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,alprazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html,2015-09-10 14:36:47 -0400,drug-drug-interaction,evidence-supports,Anticonvulsants — Patients on stable doses of phenytoin and carbamazepine have developed elevated plasma anticonvulsant concentrations and clinical anticonvulsant toxicity following initiation of concomitant fluoxetine treatment.,ncit:positive,ncit:Qualitative,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,fluoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html,2015-09-10 14:36:47 -0400,drug-drug-interaction,evidence-supports,Lithium — There have been reports of both increased and decreased lithium levels when lithium was used concomitantly with fluoxetine. Cases of lithium toxicity and increased serotonergic effects have been reported. Lithium levels should be monitored when these drugs are administered concomitantly [see Warnings and Precautions (5.2)]. ,ncit:positive,ncit:Qualitative,Lithium,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,fluoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html,2015-09-10 14:36:47 -0400,DDI-clinical-trial,evidence-supports,"Tricyclic Antidepressants (TCAs) — In 2 studies, previously stable plasma levels of imipramine and desipramine have increased greater than 2- to 10-fold when fluoxetine has been administered in combination. This influence may persist for 3 weeks or longer after fluoxetine is discontinued. Thus, the dose of TCAs may need to be reduced and plasma TCA concentrations may need to be monitored temporarily when fluoxetine is coadministered or has been recently discontinued [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)]. ",ncit:positive,ncit:quantitative,fluoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,imipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Unk,UNK,UNK,Unk,UNK,UNK,Unk,Unk,Unk,UNK,UNK,Unk,UNK,UNK,2 to 10,Fold,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html,2015-09-10 14:36:47 -0400,drug-drug-interaction,evidence-supports,Anticonvulsants — Patients on stable doses of phenytoin and carbamazepine have developed elevated plasma anticonvulsant concentrations and clinical anticonvulsant toxicity following initiation of concomitant fluoxetine treatment. ,ncit:positive,ncit:Qualitative,fluoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html,2015-09-10 14:36:47 -0400,drug-drug-interaction,evidence-supports,Antipsychotics — Some clinical data suggests a possible pharmacodynamic and/or pharmacokinetic interaction between SSRIs and antipsychotics. Elevation of blood levels of haloperidol and clozapine has been observed in patients receiving concomitant fluoxetine. ,ncit:positive,ncit:Qualitative,clozapine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,fluoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html,2015-09-10 14:36:47 -0400,DDI-clinical-trial,evidence-supports,"Tricyclic Antidepressants (TCAs) — In 2 studies, previously stable plasma levels of imipramine and desipramine have increased greater than 2- to 10-fold when fluoxetine has been administered in combination. This influence may persist for 3 weeks or longer after fluoxetine is discontinued. Thus, the dose of TCAs may need to be reduced and plasma TCA concentrations may need to be monitored temporarily when fluoxetine is coadministered or has been recently discontinued [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)]. ",ncit:positive,ncit:quantitative,desipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Unk,fluoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,UNK,UNK,Unk,UNK,UNK,Unk,Unk,Unk,UNK,UNK,Unk,UNK,UNK,2 to 10,Fold,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html,2015-09-10 14:36:47 -0400,drug-drug-interaction,evidence-supports,Antipsychotics — Some clinical data suggests a possible pharmacodynamic and/or pharmacokinetic interaction between SSRIs and antipsychotics. Elevation of blood levels of haloperidol and clozapine has been observed in patients receiving concomitant fluoxetine. ,ncit:positive,ncit:Qualitative,haloperidol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,fluoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html,2015-09-09 14:15:56 -0400,DDI-clinical-trial,evidence-supports,Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam. ,ncit:negative,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,0.25,triazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,SD,Oral,1,Daily,Oral,28,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html,2015-09-09 14:15:56 -0400,DDI-clinical-trial,evidence-supports,"In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg twice a day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively. The clinical significance of these findings is unknown. ",ncit:positive,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,400,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,40,Daily,Oral,21,Daily,Oral,8,Unk,43,Percent,Increase,Unk,UNK,UNK,39,Percent,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html,2015-09-09 14:15:56 -0400,DDI-clinical-trial,evidence-supports,"Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg), a potent CYP3A4 inhibitor, decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram. ",ncit:positive,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,UNK,Oral,Unk,UNK,Oral,Unk,Unk,21,Percent,Decrease,Unk,UNK,UNK,10,Percent,Decrease,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html,2015-09-09 14:15:56 -0400,DDI-clinical-trial,evidence-supports,"Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate. Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered. ",ncit:negative,ncit:quantitative,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,400,Daily,Oral,35,Daily,Oral,14,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html,2015-09-09 14:15:56 -0400,DDI-clinical-trial,evidence-supports,Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.,ncit:negative,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,triazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,0.25,Daily,Oral,28,SD,Oral,1,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html,2015-09-09 14:15:56 -0400,DDI-clinical-trial,evidence-supports,Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline. The effect of theophylline on the pharmacokinetics of citalopram was not evaluated. ,ncit:negative,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,300,theophylline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,SD,Oral,1,Daily,Oral,21,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html,2015-09-09 14:15:56 -0400,DDI-clinical-trial,evidence-supports,"In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin. ",ncit:negative,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,1,Daily,Oral,21,SD,Oral,1,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html,2015-09-09 14:15:56 -0400,DDI-clinical-trial,evidence-supports,"Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice. Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when Lexapro and lithium are coadministered. ",ncit:negative,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,30 mmol,lithium,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,Daily,IV,5,Daily,Oral,10,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html,2015-09-09 14:15:56 -0400,DDI-clinical-trial,evidence-supports,"In vitro studies indicated that CYP3A4 and -2C19 are the primary enzymes involved in the metabolism of escitalopram. However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram. Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance.",ncit:negative,ncit:quantitative,ritonavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,20,escitalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,600,UNK,Oral,Unk,UNK,Oral,Unk,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html,2015-09-09 14:15:56 -0400,DDI-clinical-trial,evidence-supports,"In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin. ",ncit:negative,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,1,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,SD,Oral,1,Daily,Oral,21,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html,2015-09-09 14:15:56 -0400,DDI-clinical-trial,evidence-supports,"Administration of 40 mg/day racemic citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate. Prothrombin time was increased by 5%, the clinical significance of which is unknown. ",ncit:negative,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,warfarin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,UNK,UNK,Unk,Daily,Oral,21,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html,2015-09-09 14:15:56 -0400,DDI-clinical-trial,evidence-supports,"Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram. ",ncit:negative,ncit:quantitative,escitalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,20,ritonavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,600,UNK,Oral,Unk,UNK,Oral,Unk,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html,2015-09-09 14:15:56 -0400,DDI-clinical-trial,evidence-supports,"In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Racemic citalopram did not alter the mean AUC or Cmax of pimozide. The mechanism of this pharmacodynamic interaction is not known. ",ncit:negative,ncit:quantitative,pimozide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,2,SD,Oral,1,Daily,Oral,11,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html,2015-09-09 14:15:56 -0400,DDI-clinical-trial,evidence-supports,"Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg), a potent CYP3A4 inhibitor, decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram. ",ncit:negative,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,400,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,UNK,Oral,Unk,UNK,Oral,Unk,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html,2015-09-09 14:15:56 -0400,DDI-clinical-trial,evidence-supports,"In vitro studies did not reveal an inhibitory effect of escitalopram on CYP2D6. In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism. However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine. The clinical significance of this finding is unknown. Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6. ",ncit:positive,ncit:quantitative,desipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,20,escitalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,50,SD,Oral,1,Daily,Oral,21,Unk,100,Percent,Increase,Unk,UNK,UNK,40,Percent,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html,2015-09-09 14:15:56 -0400,DDI-clinical-trial,evidence-supports,"Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice. Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when Lexapro and lithium are coadministered",ncit:negative,ncit:quantitative,lithium,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,30 mmol,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,Daily,Oral,10,Daily,IV,5,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html,2015-09-09 14:15:56 -0400,DDI-clinical-trial,evidence-supports,Administration of 20 mg/day Lexapro for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg). Increased metoprolol plasma levels have been associated with decreased cardioselectivity. Coadministration of Lexapro and metoprolol had no clinically significant effects on blood pressure or heart rate. ,ncit:positive,ncit:quantitative,Lexapro,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,100,metoprolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,20,SD,Oral,1,Daily,Oral,21,Unk,82,Percent,Increase,Unk,UNK,UNK,50,Percent,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html,2015-09-09 14:15:56 -0400,DDI-clinical-trial,evidence-supports,"Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram. ",ncit:negative,ncit:quantitative,escitalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,600,ritonavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,20,UNK,Oral,Unk,UNK,Oral,Unk,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html,2015-09-09 13:53:12 -0400,DDI-clinical-trial,evidence-supports,"Imipramine and Other Tricyclic Antidepressants (TCAs) - In vitro studies suggest that citalopram is a relatively weak inhibitor of CYP2D6. Coadministration of Celexa (40 mg/day for 10 days) with the TCA imipramine (single dose of 100 mg), a substrate for CYP2D6, did not significantly affect the plasma concentrations of imipramine or citalopram. However, the concentration of the imipramine metabolite desipramine was increased by approximately 50%. The clinical significance of the desipramine change is unknown. Nevertheless, caution is indicated in the coadministration of TCAs with Celexa.",ncit:positive,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,desipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,40,UNK,UNK,Unk,Daily,Oral,10,Unk,Unk,UNK,UNK,Unk,UNK,UNK,50,Percent,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html,2015-09-09 13:53:12 -0400,DDI-clinical-trial,evidence-supports,"Warfarin - Administration of 40 mg/day Celexa for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate. Prothrombin time was increased by 5%, the clinical significance of which is unknown.",ncit:negative,ncit:quantitative,Celexa,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,Unk,warfarin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,UNK,UNK,Unk,Daily,Oral,21,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html,2015-09-09 13:53:12 -0400,DDI-clinical-trial,evidence-supports,Theophylline - Combined administration of Celexa (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline. The effect of theophylline on the pharmacokinetics of citalopram was not evaluated.,ncit:negative,ncit:quantitative,theophylline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,Celexa,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,300,SD,Oral,1,Daily,Oral,21,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html,2015-09-09 13:53:12 -0400,DDI-clinical-trial,evidence-supports,"Ketoconazole - Combined administration of Celexa (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.",ncit:negative,ncit:quantitative,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,UNK,Oral,Unk,UNK,Oral,Unk,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html,2015-09-09 13:53:12 -0400,DDI-clinical-trial,evidence-supports,"Carbamazepine - Combined administration of Celexa (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate. Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of citalopram should be considered if the two drugs are coadministered.",ncit:negative,ncit:quantitative,Celexa,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,400,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,Daily,Oral,35,Daily,Oral,14,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html,2015-09-09 13:53:12 -0400,DDI-clinical-trial,evidence-supports,Triazolam - Combined administration of Celexa (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.,ncit:negative,ncit:quantitative,triazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,0.25,Celexa,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:object-drug-of-interaction,40,Daily,Oral,28,SD,Oral,1,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html,2015-09-09 13:53:12 -0400,DDI-clinical-trial,evidence-supports,Metoprolol - Administration of 40 mg/day Celexa for 22 days resulted in a two-fold increase in the plasma levels of the beta-adrenergic blocker metoprolol. Increased metoprolol plasma levels have been associated with decreased cardioselectivity. Coadministration of Celexa and metoprolol had no clinically significant effects on blood pressure or heart rate.,ncit:positive,ncit:quantitative,Celexa,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,Unk,metoprolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,UNK,UNK,Unk,Daily,Oral,22,Unk,Unk,UNK,UNK,Unk,UNK,UNK,2,Fold,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html,2015-09-09 13:53:12 -0400,DDI-clinical-trial,evidence-supports,"Ketoconazole - Combined administration of Celexa (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.",ncit:positive,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,UNK,Oral,Unk,UNK,Oral,Unk,Unk,21,Percent,Decrease,10,Percent,Decrease,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html,2015-09-09 13:53:12 -0400,DDI-clinical-trial,evidence-supports,"Imipramine and Other Tricyclic Antidepressants (TCAs) - In vitro studies suggest that citalopram is a relatively weak inhibitor of CYP2D6. Coadministration of Celexa (40 mg/day for 10 days) with the TCA imipramine (single dose of 100 mg), a substrate for CYP2D6, did not significantly affect the plasma concentrations of imipramine or citalopram. However, the concentration of the imipramine metabolite desipramine was increased by approximately 50%. The clinical significance of the desipramine change is unknown. Nevertheless, caution is indicated in the coadministration of TCAs with Celexa.",ncit:negative,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,Imipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,100,Daily,Oral,10,SD,Oral,1,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html,2015-09-09 13:53:12 -0400,DDI-clinical-trial,evidence-supports,"Imipramine and Other Tricyclic Antidepressants (TCAs) - In vitro studies suggest that citalopram is a relatively weak inhibitor of CYP2D6. Coadministration of Celexa (40 mg/day for 10 days) with the TCA imipramine (single dose of 100 mg), a substrate for CYP2D6, did not significantly affect the plasma concentrations of imipramine or citalopram. However, the concentration of the imipramine metabolite desipramine was increased by approximately 50%. The clinical significance of the desipramine change is unknown. Nevertheless, caution is indicated in the coadministration of TCAs with Celexa.",ncit:negative,ncit:quantitative,imipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,100,SD,Oral,1,Daily,Oral,10,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html,2015-09-09 13:53:12 -0400,DDI-clinical-trial,evidence-supports,Triazolam - Combined administration of Celexa (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.,ncit:negative,ncit:quantitative,triazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,0.25,SD,Oral,1,Daily,Oral,28,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html,2015-09-09 13:53:12 -0400,DDI-clinical-trial,evidence-supports,"Pimozide - In a controlled study, a single dose of pimozide 2 mg co-administered with citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Citalopram did not alter the mean AUC or Cmax of pimozide. The mechanism of this pharmacodynamic interaction is not known.",ncit:negative,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,2,pimozide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,SD,Oral,1,Daily,Oral,11,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html,2015-09-09 13:25:44 -0400,DDI-clinical-trial,evidence-supports,"Digoxin - In subjects who had received 21 days of 40 mg/day Celexa, combined administration of Celexa and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.",ncit:negative,ncit:quantitative,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,1,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,Daily,Oral,21,SD,Oral,1,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html,2015-09-09 13:25:44 -0400,DDI-clinical-trial,evidence-supports,"Lithium - Coadministration of Celexa (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice. Because lithium may enhance the serotonergic effects of citalopram, caution should be exercised when Celexa and lithium are coadministered.",ncit:negative,ncit:quantitative,lithium,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,30 mmol,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,Daily,Oral,10,Daily,IV,5,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html,2015-09-09 13:25:44 -0400,DDI-clinical-trial,evidence-supports,"Digoxin - In subjects who had received 21 days of 40 mg/day Celexa, combined administration of Celexa and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.",ncit:negative,ncit:quantitative,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,1,SD,Oral,1,Daily,Oral,21,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html,2015-09-09 13:25:44 -0400,DDI-clinical-trial,evidence-supports,"Cimetidine - In subjects who had received 21 days of 40 mg/day Celexa, combined administration of 400 mg twice a day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively. ",ncit:positive,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,400,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,40,Daily,Oral,21,BID,Oral,8,Unk,43,Percent,Increase,Unk,UNK,UNK,39,Percent,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html,2015-09-09 13:25:44 -0400,drug-drug-interaction,evidence-supports,"CYP3A4 and CYP 2C19 inhibitors: Since CYP3A4 and CYP 2C19 are the primary enzymes involved in the metabolism of citalopram, it is expected that potent inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, and macrolide antibiotics) and potent inhibitors of CYP2C19 (e.g., omeprazole) might decrease the clearance of citalopram. However, coadministration of citalopram and the potent CYP3A4 inhibitor ketoconazole did not significantly affect the pharmacokinetics of citalopram. Celexa 20 mg/day is the maximum recommended dose in patients taking concomitant cimetidine or another CYP2C19 inhibitor, because of the risk of QT prolongation (see WARNINGS and DOSAGE AND ADMINISTRATION).",ncit:negative,ncit:Qualitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html,2015-09-09 13:25:44 -0400,DDI-clinical-trial,evidence-supports,"Lithium - Coadministration of Celexa (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice. Because lithium may enhance the serotonergic effects of citalopram, caution should be exercised when Celexa and lithium are coadministered.",ncit:negative,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,30 mmol,lithium,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,40,Daily,IV,5,Daily,Oral,10,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 16:19:40 -0400,DDI-clinical-trial,evidence-supports,"Warfarin    Warfarin is a substrate for CYP2C9 and CYP3A4 metabolism pathways. In healthy volunteers titrated with Coumadin®# (warfarin sodium) to clinical levels of anticoagulation (INR of 1.5 to 2), co-administration with EMSAM 6 mg per 24 hours for 7 days did not affect the pharmacokinetics of the individual warfarin enantiomers. EMSAM did not alter the clinical pharmacodynamic effects of warfarin as measured by INR, Factor VII or Factor X levels [see Drug Interactions (7.4) and (7.5)].",ncit:negative,ncit:quantitative,warfarin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,6,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,Unk,UNK,UNK,Unk,Daily,Oral,7,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 16:19:40 -0400,DDI-clinical-trial,evidence-supports,"Levothyroxine    In healthy subjects who had received EMSAM 6 mg per 24 hours for 10 days, single dose administration with levothyroxine (150 mcg) did not alter the pharmacokinetics of either selegiline or levothyroxine [see Drug Interactions (7.4) and (7.5)].",ncit:negative,ncit:quantitative,levothyroxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,6,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,0.15,SD,Oral,1,Daily,Oral,10,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 16:19:40 -0400,DDI-clinical-trial,evidence-supports,"Risperidone    In subjects who had received EMSAM 6 mg per 24 hours for 10 days, co-administration with risperidone (2 mg per day for 7 days), a substrate for CYP2D6, did not affect the pharmacokinetics of selegiline or risperidone [see Drug Interactions (7.4) and (7.5)].    Warfarin",ncit:negative,ncit:quantitative,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,2,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,6,Daily,Oral,7,Daily,Oral,10,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 16:19:40 -0400,DDI-clinical-trial,evidence-supports,"Olanzapine    In subjects who had received EMSAM 6 mg per 24 hours for 10 days, co-administration with olanzapine, a substrate for CYP1A2, CYP2D6, and possibly CYP2A6, did not affect the pharmacokinetics of selegiline or olanzapine [see Drug Interactions (7.4) and (7.5)].",ncit:negative,ncit:quantitative,olanzapine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,6,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,Unk,UNK,UNK,Unk,Daily,Oral,10,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 16:19:40 -0400,DDI-clinical-trial,evidence-supports,"Ketoconazole    Seven-day treatment with ketoconazole (200 mg per day), a potent inhibitor of CYP3A4, did not affect the steady-state pharmacokinetics of selegiline in subjects who received EMSAM 6 mg per 24 hours for 7 days and no differences in the pharmacokinetics of ketoconazole were observed [see Drug Interactions (7.4) and (7.5)]. ",ncit:negative,ncit:quantitative,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,200,selegiline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,6,Daily,Oral,7,Daily,Oral,7,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 16:19:40 -0400,DDI-clinical-trial,evidence-supports,"Olanzapine    In subjects who had received EMSAM 6 mg per 24 hours for 10 days, co-administration with olanzapine, a substrate for CYP1A2, CYP2D6, and possibly CYP2A6, did not affect the pharmacokinetics of selegiline or olanzapine [see Drug Interactions (7.4) and (7.5)].",ncit:negative,ncit:quantitative,olanzapine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:object-drug-of-interaction,6,Daily,Oral,10,UNK,UNK,Unk,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 16:19:40 -0400,DDI-clinical-trial,evidence-supports,"Risperidone    In subjects who had received EMSAM 6 mg per 24 hours for 10 days, co-administration with risperidone (2 mg per day for 7 days), a substrate for CYP2D6, did not affect the pharmacokinetics of selegiline or risperidone [see Drug Interactions (7.4) and (7.5)].",ncit:negative,ncit:quantitative,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:object-drug-of-interaction,6,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,2,Daily,Oral,10,Daily,Oral,7,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 16:19:40 -0400,DDI-clinical-trial,evidence-supports,"Phenylpropanolamine (PPA)    In subjects who had received EMSAM 6 mg per 24 hours for 9 days, co-administration with PPA (25 mg every 4 hours for 24 hours) did not affect the pharmacokinetics of PPA. There was a higher incidence of significant blood pressure elevations with the co-administration of EMSAM and PPA than with PPA alone, suggesting a possible pharmacodynamic interaction [see Drug Interactions (7.4) and (7.5)]. ",ncit:negative,ncit:quantitative,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,25,PPA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,6,UNK,Oral,Unk,Daily,Oral,9,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 16:19:40 -0400,DDI-clinical-trial,evidence-supports,"Pseudoephedrine    EMSAM 6 mg per 24 hours for 10 days, co-administered with pseudoephedrine (60 mg, 3 times a day) did not affect the pharmacokinetics of pseudoephedrine. There were no clinically significant changes in blood pressure during pseudoephedrine administration alone, or in combination with EMSAM [see Drug Interactions (7.4) and (7.5)]. ",ncit:negative,ncit:quantitative,pseudoephedrine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,6,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,60,TID,Oral,Unk,Daily,Oral,10,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 16:19:40 -0400,DDI-clinical-trial,evidence-supports,"Levothyroxine    In healthy subjects who had received EMSAM 6 mg per 24 hours for 10 days, single dose administration with levothyroxine (150 mcg) did not alter the pharmacokinetics of either selegiline or levothyroxine [see Drug Interactions (7.4) and (7.5)].",ncit:negative,ncit:quantitative,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:object-drug-of-interaction,6,levothyroxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,0.15,Daily,Oral,10,SD,Oral,1,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:51:47 -0400,DDI-clinical-trial,evidence-supports,"Carbamazepine    Carbamazepine is an enzyme inducer and typically causes decreases in drug exposure; however, approximately 2-fold increased systemic exposure of selegiline and its metabolites, L-amphetamine and L-methamphetamine were seen after single application of EMSAM 6 mg per 24 hours in subjects who had received carbamazepine (400 mg per day) for 14 days. Changes in plasma selegiline concentrations were nearly 2-fold and variable across the subject population. Such increases may increase the risk of a hypertensive crisis when carbamazepine is used with EMSAM at any dose [see Contraindications (4), Warnings and Precautions (5.3) and Drug Interaction (7.4)].",ncit:positive,ncit:quantitative,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,L-methamphetamine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,400,UNK,UNK,Unk,Daily,Oral,14,Unk,2,Fold,Increase,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:51:47 -0400,DDI-clinical-trial,evidence-supports,"Ibuprofen    In subjects who had received EMSAM 6 mg per 24 hours for 11 days, combined administration with the CYP2C9 substrate ibuprofen (800 mg single dose) did not affect the pharmacokinetics of either selegiline or ibuprofen [see Drug Interactions (7.4) and (7.5)]. ",ncit:negative,ncit:quantitative,ibuprofen,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,6,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,800,SD,Oral,1,Daily,Oral,11,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:51:47 -0400,DDI-clinical-trial,evidence-supports,"Ibuprofen    In subjects who had received EMSAM 6 mg per 24 hours for 11 days, combined administration with the CYP2C9 substrate ibuprofen (800 mg single dose) did not affect the pharmacokinetics of either selegiline or ibuprofen [see Drug Interactions (7.4) and (7.5)]. ",ncit:negative,ncit:quantitative,ibuprofen,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,800,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:object-drug-of-interaction,6,Daily,Oral,11,SD,Oral,1,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:51:47 -0400,DDI-clinical-trial,evidence-supports,"Carbamazepine    Carbamazepine is an enzyme inducer and typically causes decreases in drug exposure; however, approximately 2-fold increased systemic exposure of selegiline and its metabolites, L-amphetamine and L-methamphetamine were seen after single application of EMSAM 6 mg per 24 hours in subjects who had received carbamazepine (400 mg per day) for 14 days. Changes in plasma selegiline concentrations were nearly 2-fold and variable across the subject population. Such increases may increase the risk of a hypertensive crisis when carbamazepine is used with EMSAM at any dose [see Contraindications (4), Warnings and Precautions (5.3) and Drug Interaction (7.4)].",ncit:positive,ncit:quantitative,selegiline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,400,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,6,SD,Oral,1,Daily,Oral,14,Unk,2,Fold,Increase,Unk,UNK,UNK,2,Fold,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:51:47 -0400,DDI-clinical-trial,evidence-supports,"Carbamazepine    Carbamazepine is an enzyme inducer and typically causes decreases in drug exposure; however, approximately 2-fold increased systemic exposure of selegiline and its metabolites, L-amphetamine and L-methamphetamine were seen after single application of EMSAM 6 mg per 24 hours in subjects who had received carbamazepine (400 mg per day) for 14 days. Changes in plasma selegiline concentrations were nearly 2-fold and variable across the subject population. Such increases may increase the risk of a hypertensive crisis when carbamazepine is used with EMSAM at any dose [see Contraindications (4), Warnings and Precautions (5.3) and Drug Interaction (7.4)].",ncit:positive,ncit:quantitative,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,L-amphetamine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,400,UNK,UNK,Unk,Daily,Oral,14,Unk,2,Fold,Increase,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:51:47 -0400,DDI-clinical-trial,evidence-supports,"Ketoconazole    Seven-day treatment with ketoconazole (200 mg per day), a potent inhibitor of CYP3A4, did not affect the steady-state pharmacokinetics of selegiline in subjects who received EMSAM 6 mg per 24 hours for 7 days and no differences in the pharmacokinetics of ketoconazole were observed [see Drug Interactions (7.4) and (7.5)]. ",ncit:negative,ncit:quantitative,selegiline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,200,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,6,Daily,Oral,7,Daily,Oral,7,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:45:10 -0400,DDI-clinical-trial,evidence-supports,"Alprazolam    In subjects who had received EMSAM 6 mg per 24 hours for 7 days, co-administration with alprazolam (15 mg per day), a CYP3A4 and CYP3A5 substrate, did not affect the pharmacokinetics of alprazolam or selegiline [see Drug Interactions (7.4) and (7.5)]. ",ncit:negative,ncit:quantitative,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,15,alprazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,6,Daily,Oral,7,Daily,Oral,7,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:45:10 -0400,DDI-clinical-trial,evidence-supports,"Alprazolam    In subjects who had received EMSAM 6 mg per 24 hours for 7 days, co-administration with alprazolam (15 mg per day), a CYP3A4 and CYP3A5 substrate, did not affect the pharmacokinetics of alprazolam or selegiline [see Drug Interactions (7.4) and (7.5)]. ",ncit:negative,ncit:quantitative,alprazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,15,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:object-drug-of-interaction,6,Daily,Oral,7,Daily,Oral,7,Unk,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:43:15 -0400,drug-drug-interaction,evidence-supports,"Carbamazepine is contraindicated with MAOIs, including selegiline [see Contraindications (4), Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)]. ",ncit:positive,ncit:Qualitative,selegiline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,Carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:43:15 -0400,drug-drug-interaction,evidence-supports,"No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. ",ncit:negative,ncit:Qualitative,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:42:22 -0400,drug-drug-interaction,evidence-supports,"No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. ",ncit:negative,ncit:Qualitative,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,alprazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:42:22 -0400,drug-drug-interaction,evidence-supports,"No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.",ncit:negative,ncit:Qualitative,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,ibuprofen,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:42:22 -0400,drug-drug-interaction,evidence-supports,"No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. ",ncit:negative,ncit:Qualitative,ibuprofen,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:42:22 -0400,drug-drug-interaction,evidence-supports,"No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. ",ncit:negative,ncit:Qualitative,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,olanzapine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:42:22 -0400,drug-drug-interaction,evidence-supports,"No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.",ncit:negative,ncit:Qualitative,levothyroxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:42:22 -0400,drug-drug-interaction,evidence-supports,"No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.",ncit:negative,ncit:Qualitative,olanzapine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:42:22 -0400,drug-drug-interaction,evidence-supports,"No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs. ",ncit:negative,ncit:Qualitative,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,alprazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:42:22 -0400,drug-drug-interaction,evidence-supports,"No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.",ncit:negative,ncit:Qualitative,warfarin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:42:22 -0400,drug-drug-interaction,evidence-supports,"No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. ",ncit:negative,ncit:Qualitative,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:42:22 -0400,drug-drug-interaction,evidence-supports,"No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.",ncit:negative,ncit:Qualitative,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,risperdione,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html,2015-09-03 15:42:22 -0400,drug-drug-interaction,evidence-supports,"No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. ",ncit:negative,ncit:Qualitative,EMSAM,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,levothyroxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html,2015-08-20 13:57:35 -0400,drug-drug-interaction,evidence-supports,"Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with GILENYA. When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)].",ncit:positive,ncit:Qualitative,GILENYA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,mitoxantrone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html,2015-08-20 13:57:35 -0400,drug-drug-interaction,evidence-supports,"Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)].",ncit:positive,ncit:Qualitative,GILENYA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,diltiazem,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html,2015-08-20 13:57:35 -0400,drug-drug-interaction,evidence-supports,"Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with GILENYA. When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)].",ncit:positive,ncit:Qualitative,GILENYA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html,2015-08-20 13:57:35 -0400,drug-drug-interaction,evidence-supports,"Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)]",ncit:positive,ncit:Qualitative,calcium channel blockers,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group,dikbD2R:object-drug-of-interaction,,GILENYA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html,2015-08-20 13:57:35 -0400,drug-drug-interaction,evidence-supports,"Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)]",ncit:positive,ncit:Qualitative,beta blockers,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group,dikbD2R:object-drug-of-interaction,,GILENYA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html,2015-08-20 13:57:35 -0400,drug-drug-interaction,evidence-supports,"Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)].",ncit:positive,ncit:Qualitative,GILENYA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html,2015-08-20 13:57:35 -0400,drug-drug-interaction,evidence-supports,"Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)].",ncit:positive,ncit:Qualitative,GILENYA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html,2015-08-20 13:57:35 -0400,drug-drug-interaction,evidence-supports,"Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with GILENYA. When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)].",ncit:positive,ncit:Qualitative,natalizumab,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,GILENYA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html,2015-08-20 13:53:28 -0400,DDI-clinical-trial,evidence-supports,"The blood levels of fingolimod and fingolimod-phosphate are increased by 1.7-fold when used concomitantly with ketoconazole. Patients who use GILENYA and systemic ketoconazole concomitantly should be closely monitored, as the risk of adverse reactions is greater.",ncit:positive,ncit:quantitative,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,fingolimod,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Unk,UNK,UNK,Unk,UNK,UNK,Unk,Unk,1.7,Fold,Increase,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 13:06:41 -0400,DDI-clinical-trial,evidence-supports,"Repeated doses of teriflunomide decreased mean Cmax and AUC of caffeine by 18% and 55%, respectively, suggesting that teriflunomide may be a weak inducer of CYP1A2 in vivo.",ncit:positive,ncit:quantitative,caffeine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Unk,teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,UNK,UNK,Unk,UNK,UNK,Unk,Unk,55,Percent,Increase,Unk,UNK,UNK,18,Percent,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 13:06:41 -0400,DDI-clinical-trial,evidence-supports,"There was an increase in mean ethinylestradiol Cmax and AUC0–24 (1.58- and 1.54-fold, respectively) and levonorgestrel Cmax and AUC0–24 (1.33- and 1.41-fold, respectively) following repeated doses of teriflunomide [see Drug Interactions (7)].",ncit:positive,ncit:quantitative,levonorgestrel,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Unk,teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,UNK,UNK,Unk,UNK,UNK,Unk,Unk,1.41,Fold,Increase,Unk,UNK,UNK,1.33,Fold,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 13:06:41 -0400,DDI-clinical-trial,evidence-supports,"There was an increase in mean ethinylestradiol Cmax and AUC0–24 (1.58- and 1.54-fold, respectively) and levonorgestrel Cmax and AUC0–24 (1.33- and 1.41-fold, respectively) following repeated doses of teriflunomide [see Drug Interactions (7)].",ncit:positive,ncit:quantitative,ethinylestradiol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Unk,teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,UNK,UNK,Unk,UNK,UNK,Unk,Unk,1.54,Fold,Increase,Unk,UNK,UNK,1.58,Fold,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 13:06:41 -0400,DDI-clinical-trial,evidence-supports,"There was an increase in mean repaglinide Cmax and AUC (1.7- and 2.4-fold, respectively), following repeated doses of teriflunomide and a single dose of 0.25 mg repaglinide, suggesting that teriflunomide is an inhibitor of CYP2C8 in vivo. The magnitude of interaction could be higher at the recommended repaglinide dose [see Drug Interactions (7)].",ncit:positive,ncit:quantitative,repaglinide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Unk,teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,0.25,SD,UNK,1,UNK,UNK,Unk,Unk,2.4,Fold,Increase,Unk,UNK,UNK,1.7,Fold,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 13:06:41 -0400,DDI-clinical-trial,evidence-supports,"There was an increase in mean cefaclor Cmax and AUC (1.43- and 1.54-fold, respectively), following repeated doses of teriflunomide, suggesting that teriflunomide is an inhibitor of organic anion transporter 3 (OAT3) in vivo [see Drug Interactions (7)].",ncit:positive,ncit:quantitative,cefaclor,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Unk,teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,UNK,UNK,Unk,UNK,UNK,Unk,Unk,1.54,Fold,Increase,Unk,UNK,UNK,1.43,Fold,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 13:06:41 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).",ncit:negative,ncit:Qualitative,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,metoprolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 13:06:41 -0400,DDI-clinical-trial,evidence-supports,"There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively), following repeated doses of teriflunomide , suggesting that teriflunomide is an inhibitor of BCRP transporter and organic anion transporting polypeptide 1B1 and 1B3 (OATP1B1/1B3) [see Drug Interactions (7)].",ncit:positive,ncit:quantitative,rosuvastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Unk,teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,UNK,UNK,Unk,UNK,UNK,Unk,Unk,2.51,Fold,Increase,Unk,UNK,UNK,2.65,Fold,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 13:06:41 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).",ncit:negative,ncit:Qualitative,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,warfarin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 13:06:41 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).",ncit:negative,ncit:Qualitative,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,bupropion,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 13:06:41 -0400,drug-drug-interaction,evidence-supports,Potent CYP and transporter inducers: Rifampin did not affect the pharmacokinetics of teriflunomide.,ncit:negative,ncit:Qualitative,teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,Rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 13:06:41 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).",ncit:negative,ncit:Qualitative,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,midazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 13:06:41 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).",ncit:negative,ncit:Qualitative,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 12:53:42 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)]",ncit:positive,ncit:Qualitative,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,rosuvastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 12:50:04 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,nateglinide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 12:50:04 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,rosuvastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 12:50:04 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)]",ncit:positive,ncit:Qualitative,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,repaglinide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 12:50:04 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)]",ncit:positive,ncit:Qualitative,pravastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 12:50:04 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,simvastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 12:50:04 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,atorvastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 12:50:04 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,mitoxantrone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 12:50:04 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)]",ncit:positive,ncit:Qualitative,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,methotrexate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 12:50:04 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 11:48:50 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,zidovudine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 11:48:50 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,ciprofloxacin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 11:48:50 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,methotrexate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 11:48:50 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,cefaclor,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 11:48:50 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 11:48:50 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,penicillin G,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 11:48:50 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,furosemide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 11:48:50 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,ketoprofen,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 11:43:54 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide may be a weak inducer of CYP1A2 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,theophylline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 11:43:54 -0400,drug-drug-interaction,evidence-supports,AUBAGIO may increase the systemic exposures of ethinylestradiol and levonorgestrel. Consideration should be given to the type or dose of contraceptives used in combination with AUBAGIO [see Clinical Pharmacology (12.3)].,ncit:positive,ncit:Qualitative,ethinylestradiol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,AUBAGIO,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 11:43:54 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide may be a weak inducer of CYP1A2 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required [see Clinical Pharmacology (12.3)]",ncit:positive,ncit:Qualitative,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,tizanidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 11:43:54 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide may be a weak inducer of CYP1A2 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,alosetron,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 11:43:54 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide may be a weak inducer of CYP1A2 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,duloxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 11:38:24 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide is an inhibitor of CYP2C8 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,repaglinide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 11:38:24 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide is an inhibitor of CYP2C8 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,rosiglitazone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 11:38:24 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide is an inhibitor of CYP2C8 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,paclitaxel,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 11:38:24 -0400,drug-drug-interaction,evidence-supports,AUBAGIO may increase the systemic exposures of ethinylestradiol and levonorgestrel. Consideration should be given to the type or dose of contraceptives used in combination with AUBAGIO [see Clinical Pharmacology (12.3)].,ncit:positive,ncit:Qualitative,AUBAGIO,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,levonorgestrel,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html,2015-08-20 11:38:24 -0400,drug-drug-interaction,evidence-supports,"Teriflunomide is an inhibitor of CYP2C8 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:Qualitative,pioglitazone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,Teriflunomide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html,2015-08-20 11:32:27 -0400,drug-drug-interaction,evidence-supports,"In a separate clinical pharmacokinetic interaction study of healthy subjects, co-administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone [see Drug Interactions (7.1)].",ncit:negative,ncit:Qualitative,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,abiraterone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html,2015-08-20 11:32:27 -0400,DDI-clinical-trial,evidence-supports,"In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of pioglitazone was increased by 46% when pioglitazone was given together with a single dose of 1,000 mg abiraterone acetate [see Drug Interactions (7.2)].",ncit:positive,ncit:quantitative,pioglitazone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,1000,abiraterone acetate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,UNK,UNK,Unk,SD,UNK,1,Unk,46,Percent,Increase,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html,2015-08-20 11:30:25 -0400,DDI-clinical-trial,evidence-supports,"Abiraterone is a substrate of CYP3A4, in vitro. In a clinical pharmacokinetic interaction study of healthy subjects pretreated with a strong CYP3A4 inducer (rifampin, 600 mg daily for 6 days) followed by a single dose of abiraterone acetate 1,000 mg, the mean plasma AUC∞ of abiraterone was decreased by 55% [see Drug Interactions (7.1)].",ncit:positive,ncit:quantitative,abiraterone acetate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,600,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,1000,SD,UNK,1,Daily,UNK,6,Unk,55,Percent,Decrease,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html,2015-08-20 11:30:25 -0400,DDI-clinical-trial,evidence-supports,"In a clinical study to determine the effects of abiraterone acetate 1,000 mg daily (plus prednisone 5 mg twice daily) on a single 100 mg dose of the CYP1A2 substrate theophylline, no increase in systemic exposure of theophylline was observed.",ncit:negative,ncit:quantitative,theophylline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,1000,abiraterone acetate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,100,SD,UNK,1,Daily,UNK,Unk,Unk,0,Percent,Increase,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html,2015-08-20 11:17:13 -0400,DDI-clinical-trial,evidence-supports,"In an in vivo drug-drug interaction trial, the Cmax and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively when dextromethorphan 30 mg was given with abiraterone acetate 1,000 mg daily (plus prednisone 5 mg twice daily). The AUC for dextrorphan, the active metabolite of dextromethorphan, increased approximately 1.3 fold [see Drug Interactions (7.2)].",ncit:positive,ncit:quantitative,abiraterone acetate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,dextrorphan,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,1000,UNK,UNK,Unk,Daily,UNK,Unk,Unk,1.3,Fold,Increase,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html,2015-08-20 11:17:13 -0400,DDI-clinical-trial,evidence-supports,"In an in vivo drug-drug interaction trial, the Cmax and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively when dextromethorphan 30 mg was given with abiraterone acetate 1,000 mg daily (plus prednisone 5 mg twice daily). The AUC for dextrorphan, the active metabolite of dextromethorphan, increased approximately 1.3 fold [see Drug Interactions (7.2)].",ncit:positive,ncit:quantitative,dextromethorphan,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,1000,abiraterone acetate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,30,UNK,UNK,Unk,Daily,UNK,Unk,Unk,2.9,Fold,Increase,Unk,UNK,UNK,2.8,Fold,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html,2015-08-20 11:10:08 -0400,DDI-clinical-trial,evidence-supports,"In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of pioglitazone (CYP2C8 substrate) was increased by 46% when pioglitazone was given together with a single dose of 1,000 mg abiraterone acetate. Therefore, patients should be monitored closely for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic index if used concomitantly with ZYTIGA [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:quantitative,abiraterone acetate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,pioglitazone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,1000,UNK,UNK,Unk,SD,UNK,1,Unk,46,Percent,Increase,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html,2015-08-20 11:10:08 -0400,drug-drug-interaction,evidence-supports,"In a dedicated drug interaction trial, co-administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone [see Clinical Pharmacology (12.3)].",ncit:negative,ncit:Qualitative,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,abiraterone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html,2015-08-20 11:10:08 -0400,DDI-clinical-trial,evidence-supports,"Based on in vitro data, ZYTIGA is a substrate of CYP3A4.    In a dedicated drug interaction trial, co-administration of rifampin, a strong CYP3A4 inducer, decreased exposure of abiraterone by 55%. Avoid concomitant strong CYP3A4 inducers during ZYTIGA treatment. If a strong CYP3A4 inducer must be co-administered, increase the ZYTIGA dosing frequency [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].",ncit:positive,ncit:quantitative,abiraterone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Unk,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,UNK,UNK,Unk,UNK,UNK,Unk,Unk,55,Percent,Decrease,Unk,UNK,UNK,Unk,UNK,UNK,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html,2015-08-20 11:10:08 -0400,DDI-clinical-trial,evidence-supports,"ZYTIGA is an inhibitor of the hepatic drug-metabolizing enzymes CYP2D6 and CYP2C8. In a CYP2D6 drug-drug interaction trial, the Cmax and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively, when dextromethorphan was given with abiraterone acetate 1,000 mg daily and prednisone 5 mg twice daily. Avoid co-administration of abiraterone acetate with substrates of CYP2D6 with a narrow therapeutic index (e.g., thioridazine). If alternative treatments cannot be used, exercise caution and consider a dose reduction of the concomitant CYP2D6 substrate drug [see Clinical Pharmacology (12.3)].",ncit:positive,ncit:quantitative,dextromethorphan,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,1000,abiraterone acetate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Unk,UNK,UNK,Unk,Daily,UNK,Unk,Unk,2.9,Fold,Increase,Unk,UNK,UNK,2.8,Fold,Increase,Unk,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7c295b64-ec39-42ec-9f02-da5b42e775e1.html,2015-08-20 10:29:59 -0400,drug-drug-interaction,evidence-supports,Clinical studies have not shown any drug interactions between bicalutamide and LHRH analogs (goserelin or leuprolide). There is no evidence that bicalutamide induces hepatic enzymes.,ncit:negative,ncit:Qualitative,goserelin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,bicalutamide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7c295b64-ec39-42ec-9f02-da5b42e775e1.html,2015-08-20 10:29:59 -0400,drug-drug-interaction,evidence-supports,Clinical studies have not shown any drug interactions between bicalutamide and LHRH analogs (goserelin or leuprolide). There is no evidence that bicalutamide induces hepatic enzymes,ncit:negative,ncit:Qualitative,leuprolide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,,bicalutamide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7c295b64-ec39-42ec-9f02-da5b42e775e1.html,2015-08-20 10:29:59 -0400,DDI-clinical-trial,evidence-supports,"In vitro studies have shown that R-bicalutamide is an inhibitor of CYP 3A4 with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity. Clinical studies have shown that with co-administration of bicalutamide, mean midazolam (a CYP 3A4 substrate) levels may be increased 1.5 fold (for Cmax) and 1.9 fold (for AUC). Hence, caution should be exercised when bicalutamide is co-administered with CYP 3A4 substrates.",ncit:positive,ncit:quantitative,midazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Unk,bicalutamide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Unk,UNK,UNK,Unk,UNK,UNK,Unk,Unk,1.9,Fold,Increase,Unk,UNK,UNK,1.5,Fold,Increase,Unk,UNK,UNK
